Drug intelligence / Profile preview

FLLL12

Development stage: Preclinical
Lead developer: Marshall University
Modality: Small Molecules
Administration: Oral

Overview

FLLL12 is a synthetic curcumin analog developed to enhance the potency and pharmacokinetic properties of curcumin. It functions primarily as an activator of the NRF2 (Nuclear factor erythroid 2-related factor 2) signaling pathway, which orchestrates the cellular antioxidant response. By promoting the expression of cytoprotective genes such as HMOX-1, NQO1, and SLC7A11, FLLL12 helps mitigate oxidative stress and protect cells from carcinogenic damage. Research has demonstrated its efficacy in normal, premalignant, and malignant head and neck cancer cell lines, highlighting its potential as a chemopreventive agent. FLLL12 is reported to have a superior pharmacokinetic profile compared to natural curcumin.

Other names: curcumin analog FLLL12

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on FLLL12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FLLL12.

Explore the full profile